RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor

Although treatment with imatinib, which inhibits KIT and PDGFR, controls advanced disease in about 80% of gastrointestinal stromal tumor (GIST) patients, resistance to imatinib often develops. RACK1 (Receptor for Activated C Kinase 1) is a ribosomal protein that contributes to tumor progression by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiaodong, Xue, Anwei, Fang, Yong, Shu, Ping, Ling, Jiaqian, Hou, Yingyong, Shen, Kuntang, Qin, Jing, Sun, Yihong, Qin, Xinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924716/
https://www.ncbi.nlm.nih.gov/pubmed/26893362
http://dx.doi.org/10.18632/oncotarget.7426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924716/
https://www.ncbi.nlm.nih.gov/pubmed/26893362
http://dx.doi.org/10.18632/oncotarget.7426

Ejemplares similares